OBJECTIVE: Lobectomy is the standard of care for stage IA lung cancer. Some small retrospective studies have suggested similar results after limited resection for tumors < or =2 cm in size. The objective of the study was to compare survival after lobectomy and limited resection among Medicare patients with lung cancer. METHODS: Using the Surveillance, Epidemiology, and End Results registry, linked to Medicare records, we identified 1165 cases of stage I lung cancer < or =2 cm in size that underwent lobectomy or limited resection (segmentectomy or wedge resection). We used logistic regression to determine propensity scores for undergoing limited resection based on the patients' preoperative characteristics. Overall and lung cancer-specific survival of patients treated with lobectomy or limited resection was compared after adjusting for their propensity score. RESULTS: Overall, 196 (17%) patients underwent limited resection. For the entire sample, the adjusted hazard ratio for all cause mortality (1.09; 95% confidence interval: 0.85-1.40) or lung cancer-specific death (hazard ratio: 1.39; 95% confidence interval: 0.97-2.01) for patients undergoing limited resection were not significantly different from those having lobectomy. Similarly, we found no significant differences in overall or lung cancer-specific survival for patients treated with limited resection compared with lobectomy when data was analyzed stratifying and matching patients by their propensity scores. CONCLUSIONS: These results suggest that survival of patients >65 years of age undergoing limited resection or lobectomy for stage IA tumors < or =2 cm appears to be similar. Although these findings should be confirmed in prospective trials, our results suggest that limited resection may be an effective therapeutic alternative for these patients.
OBJECTIVE: Lobectomy is the standard of care for stage IA lung cancer. Some small retrospective studies have suggested similar results after limited resection for tumors < or =2 cm in size. The objective of the study was to compare survival after lobectomy and limited resection among Medicare patients with lung cancer. METHODS: Using the Surveillance, Epidemiology, and End Results registry, linked to Medicare records, we identified 1165 cases of stage I lung cancer < or =2 cm in size that underwent lobectomy or limited resection (segmentectomy or wedge resection). We used logistic regression to determine propensity scores for undergoing limited resection based on the patients' preoperative characteristics. Overall and lung cancer-specific survival of patients treated with lobectomy or limited resection was compared after adjusting for their propensity score. RESULTS: Overall, 196 (17%) patients underwent limited resection. For the entire sample, the adjusted hazard ratio for all cause mortality (1.09; 95% confidence interval: 0.85-1.40) or lung cancer-specific death (hazard ratio: 1.39; 95% confidence interval: 0.97-2.01) for patients undergoing limited resection were not significantly different from those having lobectomy. Similarly, we found no significant differences in overall or lung cancer-specific survival for patients treated with limited resection compared with lobectomy when data was analyzed stratifying and matching patients by their propensity scores. CONCLUSIONS: These results suggest that survival of patients >65 years of age undergoing limited resection or lobectomy for stage IA tumors < or =2 cm appears to be similar. Although these findings should be confirmed in prospective trials, our results suggest that limited resection may be an effective therapeutic alternative for these patients.
Authors: Rajwanth R Veluswamy; Grace Mhango; Marcelo Bonomi; Alfred I Neugut; Dawn L Hershman; Melissa D Aldridge; Juan P Wisnivesky Journal: Ann Am Thorac Soc Date: 2013-12
Authors: Jun-ichi Nitadori; Adam J Bograd; Kyuichi Kadota; Camelia S Sima; Nabil P Rizk; Eduardo A Morales; Valerie W Rusch; William D Travis; Prasad S Adusumilli Journal: J Natl Cancer Inst Date: 2013-08-07 Impact factor: 13.506
Authors: Brian C Gulack; Chi-Fu Jeffrey Yang; Paul J Speicher; James M Meza; Lin Gu; Xiaofei Wang; Thomas A D'Amico; Matthew G Hartwig; Mark F Berry Journal: Lung Cancer Date: 2015-10-14 Impact factor: 5.705
Authors: Kyuichi Kadota; Jun-Ichi Nitadori; Camelia S Sima; Hideki Ujiie; Nabil P Rizk; David R Jones; Prasad S Adusumilli; William D Travis Journal: J Thorac Oncol Date: 2015-05 Impact factor: 15.609
Authors: Onkar V Khullar; Theresa Gillespie; Dana C Nickleach; Yuan Liu; Kristin Higgins; Suresh Ramalingam; Joseph Lipscomb; Felix G Fernandez Journal: J Am Coll Surg Date: 2014-10-27 Impact factor: 6.113